Shalabh K. Gupta
CIK: 0001864917
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Unicycive Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- May 14, 2026UNCY
Unicycive Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
762.2K shares- - May 14, 2026UNCY
Unicycive Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
762.2K shares- - Jul 28, 2025UNCY
Unicycive Therapeutics, Inc.
Award(A)DirectStock Options
325K shares-
1-3 of 3 transactions
About Gupta Shalabh K.
Gupta Shalabh K. (SEC CIK 0001864917) files insider reports with the SEC as CEO of Unicycive Therapeutics, Inc. (UNCY).
Signal8 holds 3 ownership filings by Gupta Shalabh K., all Form 4s, filed between Jul 30, 2025 and Jun 15, 2026. Those filings report 3 transactions, from Jul 28, 2025 to May 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Gupta Shalabh K.'s filings is in MOUNTAIN VIEW, CA.
Recent filings by Gupta Shalabh K.
Other insiders filing for Unicycive Therapeutics, Inc. (UNCY)
- Manning Meredith, Director
- Kenkare-Mitra Sara, Director
- Laumas Sandeep, Director
- Gupta Pramod, EVP, Pharmaceuticals and BD
- Townsend John, CFO
- Jermasek Douglas, EVP, Corporate Strategy